InSilico Medicine Cayman TopCo

3696

The current InSilico Medicine Cayman TopCo (3696) market capitalization is approximately HK$41.89B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, InSilico Medicine Cayman TopCo's market cap fluctuates with changes in its share price and share count. Last updated: February 15, 2026 at 5:41 PM Eastern Time

In the most recently reported quarter, InSilico Medicine Cayman TopCo (3696) generated $13.73M in revenue, representing a -54.00% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: February 15, 2026 at 5:08 AM Eastern Time

In the most recently reported fiscal year, InSilico Medicine Cayman TopCo (3696) generated net income of $-17.10M, compared with $-0.21B in the prior fiscal year, representing a +91.92% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: February 15, 2026 at 5:08 AM Eastern Time

According to its latest quarterly filing, InSilico Medicine Cayman TopCo (3696) reported EBITDA of $-10.57M, representing a -555.35% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: February 15, 2026 at 5:08 AM Eastern Time

Based on the latest available data, InSilico Medicine Cayman TopCo (3696) is currently trading at a last twelve months (LTM) P/E ratio of -123.16x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: February 15, 2026 at 5:41 PM Eastern Time

In the most recently reported quarter, InSilico Medicine Cayman TopCo (3696) revenue was $13.73M. Earnings per share (EPS) for the quarter were $-0.13. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: February 15, 2026 at 5:08 AM Eastern Time

InSilico Medicine Cayman TopCo (3696) does not currently pay a dividend. Over the last twelve months (LTM), the company paid HK$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: February 15, 2026 at 5:08 AM Eastern Time

Analyst assessments of whether InSilico Medicine Cayman TopCo (3696) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: HK$73.50Consensus price target: HK$74.06Implied return: +0.76% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: February 15, 2026 at 5:41 PM Eastern Time

Based on the latest available analyst coverage, InSilico Medicine Cayman TopCo (3696) currently carries a Outperform consensus rating. Analysts' average 3696 price target is HK$74.06. Relative to the current share price of HK$73.50, this suggests a potential price change of approximately +0.76%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: February 15, 2026 at 5:41 PM Eastern Time

Like other publicly traded stocks, InSilico Medicine Cayman TopCo (3696) shares are bought and sold on stock exchanges such as SEHK and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for InSilico Medicine Cayman TopCo (3696) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 3696 to your watchlist.

InSilico Medicine Cayman TopCo trades under the ticker symbol 3696 on the SEHK stock exchange. The ticker 3696 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

InSilico Medicine Cayman TopCo (3696) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest InSilico Medicine Cayman TopCo (3696) stock peers based on overlapping products, services, and competitive dynamics:XtalPi Holdings (2228)Recursion Pharmaceuticals (RXRX)AbCellera Biologics (ABCL)Schrödinger (SDGR)Relay Therapeutics (RLAY) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to InSilico Medicine Cayman TopCo.